Open

Coming up

Don't miss

Replay


LATEST SHOWS

AFRICA NEWS

Ebola: Lockdown brings Sierra Leone capital to a halt

Read more

MEDIAWATCH

Sarkozy's political comeback: did he ever leave?

Read more

DEBATE

The World This Week

Read more

FRANCE IN FOCUS

Travel chaos: Air France pilots take industrial action

Read more

THE BUSINESS INTERVIEW

Christian Kastrop, Director of Policy Studies, OECD

Read more

AFRICA NEWS

Ebola: UN Security Council unanimously passes resolution

Read more

ENCORE!

Author Kiran Desai on early success and the Booker Prize

Read more

THE BUSINESS INTERVIEW

Tyler Brûlé, Founder and Editor-in-chief of Monocle

Read more

REPORTERS

From Sarajevo to Guantanamo, the journey of the Algerian Six

Read more

Business

EU regulators raid drugmakers' offices

Text by NEWS WIRES

Latest update : 2009-10-06

The European Commission says it has begun "surprise inspections" at the premises of European pharmaceutical giants over suspected violations of competition rules. Drugmakers are suspected of seeking to delay the launch of cheaper generic products.

AFP - Investigators carried out raids on European pharmaceutical giants on Tuesday over suspected competition violations, the European Commission said in a statement.
   
Brussels "can confirm that on October 6 commission officials started surprise inspections at the premises of certain companies active in the pharmaceutical industry," the statement said.
   
France's Sanofi-Aventis was one of those raided, a company spokesman told AFP. "Sanofi is going to cooperate with the commission," he added.
   
Belgium's UCB and Solvay, Britain's AstraZeneca, France's Servier and Germany's Bayer and Merck each said they were not targeted.
   
Officials accompanied by national inspectors were seeking evidence of "restrictive business practices and/or the abuse of a dominant market position," the commission, which polices competition in the EU, added.
   
Regulators stepped up a sector-wide probe launched in January 2008 with an investigation announced in July into the relationship between companies that patent their products as brand-named medicine, as well as their ties with generic drug producers.
   
Then, the commission said that "unilateral behaviour" by French pharmaceutical maker Les Laboratoires Servier might have hindered the entry into EU markets of generic perindopril, a cardio-vascular medicine first developed by the company.
   
The commission did not detail the companies or countries involved, and stressed that such steps follow no fixed deadlines.
 

Date created : 2009-10-06

COMMENT(S)